DanielT.MiltonMD

PubMed

• 6 citations
  Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence.
  Craig L. Slingluff, Karl D. Lewis, Robert H.I. Andtbacka, John R. Hyngstrom, Mohammed M. Milhem, Svetomir N. Markovic, Tawnya L. Bowles, Omid Hamid, Leonel Hernandez-A...> ;Journal for Immunotherapy of Cancer. 2021 Oct 1
• 244 citations
  2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
  Christopher G. Azzoli, Sarah Temin, Timothy Aliff, Sherman Baker, Julie R. Brahmer, David H. Johnson, Janessa L. Laskin, Gregory A. Masters, Daniel T. Milton, Luke Nor...> ;Journal of Clinical Oncology. 2011 Oct 1
• 401 citations
  American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell ...
  Vicki L. Keedy, Sarah Temin, Mark R. Somerfield, Mary Beth Beasley, David H. Johnson, Lisa M. McShane, Daniel T. Milton, John R. Strawn, Heather A. Wakelee, Giuseppe G...> ;Journal of Clinical Oncology. 2011 May 20
• 21 citations
  ASCO Provisional Clinical Opinion: Epidermal Growth Factor Receptor Mutation Testing in Practice
  Mary Beth Beasley, Daniel T. Milton> ;Journal of Oncology Practice. 2011 Apr 25
• 11 citations
  [American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer].
  Christopher G. Azzoli, Sherman Baker, Sarah Temin, William Pao, Timothy Aliff, Julie R. Brahmer, David H. Johnson, Janessa L. Laskin, Gregory A. Masters, Daniel T. Mil...> ;Zhongguo Fei Ai Za Zhi = Chinese Journal of Lung Cancer. 2010 Mar 1
• 810 citations
  American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
  Christopher G. Azzoli, Sherman Baker, Sarah Temin, William Pao, Timothy Aliff, Julie R. Brahmer, David H. Johnson, Janessa L. Laskin, Gregory A. Masters, Daniel T. Mil...> ;Journal of Clinical Oncology. 2009 Dec 20
• 140 citations
  Phase II Study of Pemetrexed and Carboplatin Plus Bevacizumab With Maintenance Pemetrexed and Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer
  Jyoti D. Patel, Thomas A. Hensing, Alfred Rademaker, Eric M. Hart, Matthew G. Blum, Daniel T. Milton, Philip Bonomi> ;Journal of Clinical Oncology. 2009 Jul 10
• 36 citations
  Randomized Phase II Study of Pulse Erlotinib Before or After Carboplatin and Paclitaxel in Current or Former Smokers With Advanced Non–Small-Cell Lung Cancer
  Gregory J. Riely, Naiyer A. Rizvi, Mark G. Kris, Daniel T. Milton, David B. Solit, Neal Rosen, Emir Senturk, Christopher G. Azzoli, Julie R. Brahmer, Francis M. Sirotn...> ;Journal of Clinical Oncology. 2009 Jan 10
• Pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for advanced non-squamous non-small cell lung cancer (NSC...
  Patel JD, Hensing TA, Rademaker F, Hart E, Obasaju CK, Treat J, Milton D, Bonomi PD> ;J. Clin. Oncol.. 2008-05-20
• 26 citations
  Targeting Lewis Y (Le(y)) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levels.
  Lee M. Krug, Daniel T. Milton, Achim A. Jungbluth, Lin-Chi Chen, Emilio Quaia, Neeta Pandit-Taskar, Andrew Nagel, Jessica Jones, Mark G. Kris, Ronald D. Finn, Peter Sm...> ;Journal of Thoracic Oncology. 2007 Oct 1
• 248 citations
  Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the add...
  Gregory J. Riely, Mark G. Kris, Binsheng Zhao, Tim Akhurst, Daniel T. Milton, Leslie B. Tyson, William Pao, Naiyer A. Rizvi, Lawrence H. Schwartz, Vincent A. Miller> ;Clinical Cancer Research. 2007 Sep 1
• 81 citations
  Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer.
  Daniel T. Milton, Gregory J. Riely, Christopher G. Azzoli, Jorge Gomez, Robert T. Heelan, Mark G. Kris, Lee M. Krug, William Pao, Barbara Pizzo, Naiyer A. Rizvi, Vince...> ;Cancer. 2007 Aug 1
• 3 citations
  Mitomycin-C/5-fluorouracil/leucovorin and hyperfractionated radiation therapy for rectal carcinoma: a phase II study with long-term follow-up.
  Chadi Nabhan, Avanthi Ragam, Brian L. Samuels, Daniel T. Milton, Leela M. Prasad, Arthur Hooberman, William F. Hartsell, Andi Anthony, Robert Weisman, Jacob D. Bitran> ;Clinical Colorectal Cancer. 2007 Mar 1
• 9 citations
  Molecular on/off switch.
  Daniel T. Milton, Gregory J. Riely, William Pao, Vincent A. Miller, Mark G. Kris, Robert T. Heelan> ;Journal of Clinical Oncology. 2006 Oct 20
• 65 citations
  A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer.
  Daniel T. Milton, Christopher G. Azzoli, Robert T. Heelan, Ennapadam Venkatraman, Jorge Gomez, Mark G. Kris, Lee M. Krug, William Pao, Naiyer A. Rizvi, Megan Dunne, Vi...> ;Cancer. 2006 Sep 1
• Prospective FDG-PET and CT assessment of discontinuation of erlotinib (E) or gefitinib (G) in patients with EGFR TKI sensitive non-small cell lung cancer (NSCLC) who s...
  Riely GJ, Kris MG, Schwartz LH, Akhurst T, Zhao B, Milton DT, Moore E, Tyson L, Pao W, Miller VA> ;J. Clin. Oncol.. 2006-06-20
• Targeting Lewis Y (LeY) in small cell lung cancer (SCLC) with a humanized monoclonal antibody, hu3S193.
  Krug LM, Milton D, Chen L, Jungbluth AA, Quaia E, Nagel A, Jones J, Finn R, Divgi C> ;J. Clin. Oncol.. 2006-06-20
• Intrathecal drug delivery versus comprehensive medical management as it may impact inpatient length of stay, readmission, and inpatient cost of care.
  Isaacs JD, Stearns LJ, Poling WH, Milton D, Nasternak J, Romano C> ;J. Clin. Oncol.. 2006-06-20
• Phase I/II trial of gefitinib and RAD001 (everolimus) in patients (pts) with advanced non-small cell lung cancer (NSCLC).
  Milton DT, Kris MG, Azzoli CG, Gomez JE, Heelan R, Krug LM, Pao W, Pizzo B, Rizvi NA, Miller VA> ;J. Clin. Oncol.. 2005-06-01
• 187 citations
  High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib.
  Antonio M. P. Omuro, Mark G. Kris, Vincent A. Miller, Enrico Franceschi, Neelam Shah, Daniel T. Milton, Lauren E. Abrey> ;Cancer. 2005 Jun 1
• 15 citations
  Advances in cytotoxic chemotherapy for the treatment of metastatic or recurrent non-small cell lung cancer
  Daniel T. Milton, Vincent A. Miller> ;Seminars in Oncology. 2005 Jun 1
• 14 citations
  Prompt control of bronchorrhea in patients with bronchioloalveolar carcinoma treated with gefitinib (Iressa).
  Daniel T. Milton, Mark G. Kris, Jorge Gomez, Marc B. Feinstein> ;Supportive Care in Cancer. 2005 Jan 1
• Weekly high-dose erlotinib in patients with non-small cell lung cancer (NSCLC): A phase I/II study.
  Milton DT, Miller VA, Azzoli CG, Dunne M, Gomez JE, Heelan R, Krug LM, Ramies D, Rizvi NA, Kris MG> ;J. Clin. Oncol.. 2004-07-15
• Docetaxel and oxaliplatin as first-line therapy for advanced non-small cell lung cancer: a phase II trial.
  Radhakrishnan, A., Bitran, J. D., Milton, D. T., Tolzien, K., Hallmeyer, S., Nabhan, C.> ;J Chemother. 2009 Aug 01
• Join now to see all